Sinovac Biotech Ltd (SVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 386,013 | 361,374 | 470,170 | 1,492,761 | 19,374,900 |
| Cost of Goods | 124,032 | 140,688 | 146,853 | 684,456 | 1,072,221 |
| Gross Profit | 261,981 | 220,686 | 323,317 | 808,305 | 18,302,680 |
| Operating Expenses | 752,143 | 726,909 | 1,038,153 | 1,274,828 | 749,647 |
| Operating Income | -490,130 | -505,535 | -713,983 | -466,067 | 17,553,260 |
| Interest Expense | 9,819 | 5,637 | 4,941 | 1,264 | 2,836 |
| Other Income | 237,847 | 554,009 | 634,437 | 492,569 | 12,616 |
| Pre-tax Income | -262,102 | 42,837 | -84,487 | 25,238 | 17,563,040 |
| Income Tax | -63,266 | 2,181 | 36,371 | -62,893 | 3,104,130 |
| Net Income Continuous | -198,836 | 40,656 | -120,858 | 88,131 | 14,458,910 |
| Minority Interests | -139,156 | -50,249 | -107,367 | -25,735 | 5,991,431 |
| Net Income | $-59,680 | $90,905 | $-13,491 | $113,866 | $8,467,480 |
| EPS Basic Total Ops | -0.83 | 1.27 | -0.19 | 1.08 | 85.20 |
| EPS Basic Continuous Ops | -2.77 | 0.57 | -1.68 | 0.89 | 145.59 |
| EPS Diluted Total Ops | -0.83 | 1.27 | -0.19 | 1.00 | 74.27 |
| EPS Diluted Continuous Ops | -2.77 | 0.57 | -1.68 | 0.77 | 126.83 |
| EPS Diluted Before Non-Recurring Items | -0.83 | 1.27 | -1.32 | -0.37 | 74.67 |
| EBITDA(a) | $-391,353 | $-394,256 | $-555,539 | $-311,219 | $17,637,890 |